Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
HOME > COMMENTARY
COMMENTARY
-
Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
-
New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
-
Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
-
Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
-
Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
-
Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
-
Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
-
Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
July 18, 2011
-
Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
July 4, 2011
-
Era of Competition Dawns in Market for AD Treatments
June 27, 2011
-
Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
June 20, 2011
-
Return to Full-bore Growth Strategy Risky for Taiyo Pharm
June 13, 2011
-
Why the Same Mistake Repeated? -MSD's Promotion Code Violations
June 6, 2011
-
GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
June 6, 2011
-
Effects of Changes to Accelerate Approval to Be Seen from November
May 30, 2011
-
Japan's Most Admired Pharma Companies in 2010
April 4, 2011
-
Will New Disclosure GL Promote Industry-Academia Alliances?
March 28, 2011
-
Use of Generics by Welfare Recipients
March 7, 2011
-
Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
February 21, 2011
-
Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
February 21, 2011
ページ
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…